Research

Research & Focus

BioActor’s research focus mainly revolves around two phenomena, namely the microbiome and mitochondria

Bacterial cells largely outnumber human cells and live in symbiosis with the gut. About 70% of our entire immune system resides in the gut and together with the microbiota, they are able to influence our health and wellbeing. BioActor conducts both in-vitro and clinical research in collaboration with Maastricht University and MUMC+ regarding the effects of citrus flavonoids (‘flavobiotics’) on the microbiome composition and immune health.

As for mitochondria, they act as the powerhouse of the cells. By transferring electrons from the inner membrane space through the inner membrane, mitochondria can provide our bodies with the energy storage molecule ATP. BioActor collaborates with a specialized research group at Maastricht University to study the effect of polyphenols on mitochondrial efficiency, respirational capacity and ATP generation in optimized cell lines.

Clinical Research

Clinical research through GCP-trials is an essential part of the value creation strategy of BioActor. Every BioActor product has been evaluated in one or more clinical studies. The company has an in-house clinical research group that organizes several clinical studies annually in close collaboration with principal investigators at leading university hospitals.

BioActor has an ongoing collaboration with the gastroenterology department of Maastricht University Medical Centre (MUMC) for clinical research.

If you are interested to participate in one of our clinical studies, please contact: Yala Stevens, Clinical Research Manager, yala.stevens@bioactor.com

Review in vivo/in vitro results & consultation key opinion leaders

Trial design / Protocol / Crf-design

Approval ethics committee

Recruitment participants

Conducting clinical trial

Data management & Analysis

Research Collaboration

Research collaboration is the cornerstone of BioActor’s research strategy. We have collaborations with several top universities and research institutes, whereby BioActor focuses on translational research aspects, such as PkA, clinical efficacy, product characterization, and stability.

In addition, BioActor is participating in a number of high profile European Union-supported projects.

FIBEBIOTICS

The EU project, “Dietary fibres supporting gut & immune function,” studies the bioactive (health) function of polysaccharides and generates knowledge that support health claims.

BACCHUS

“Beneficial effects of dietary bioactive peptides and polyphenols on cardiovascular health in humans.” The aim of this project is to develop tools and resources that will facilitate the generation of robust scientific evidence that can be used to support claims of a cause and effect relationship between consumption of bioactive peptides, polyphenols, and beneficial physiological effects related to cardiovascular health in humans.

NESTLE

BioActor engaged in a collaboration with Nestlé Health Science on the development of nutritional products containing BONOLIVE®. Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients, and our partners in healthcare.

INTERREG

BioActor recently started the ‘Inflavobiotics project, a project in collaboration with Prodigest, financed with a grant from the CROSSROADS program. CROSSROADS is an innovation stimulation program within the Interreg V program Flanders-Netherlands.

Bonolive®, Cordiart®, Olecol®, Watts’up®, Actiful®, Naxus®, MicrobiomeX®, Flavobiotics® and BrainBerry® are registered trademarks of BioActor B.V.